SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TR1US
- 17 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
- 02 Dec 2016 Results (n=16) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 10 Nov 2016 According to a PharmaMar media release, data from this trial will be presented at the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS).